Acquisition adds to company's recent growth in
high-technology pharmacy solutions and further accelerates the
company's commitment to Smart, Connected Care – offering a
customizable platform to optimize IV workflow
FRANKLIN
LAKES, N.J., July 28,
2022 /PRNewswire/ -- BD (Becton, Dickinson and
Company) (NYSE: BDX), a leading global medical technology company,
announced today it has acquired MedKeeper, a provider of modern,
cloud-based pharmacy management applications.
MedKeeper strategically complements BD's existing presence in
the pharmacy – where the company has pioneered solutions in
compounding, logistics workflow, controlled substance management
and inventory optimization.
MedKeeper's platform will become part of the company's existing
portfolio of connected medication management capabilities. By
combining MedKeeper's platform with BD's broad technology
expertise, the companies will work to optimize the preparation of
compounded medications – a critical need in the pharmacy today.
"Preparing the right dose for patients requires a combination of
factors – including personnel, training, and compliance. Pharmacy
leaders require IV workflow management technology that is
personalized to their needs and works within their environment,"
said Mike Garrison, Worldwide
President of Medication Management Solutions at BD. "Adding
MedKeeper to our portfolio will enable us to offer our customers
easy to use, customizable solutions that make meaningful and
incremental progress in IV workflow management."
Today, many pharmacies leverage a combination of both manual and
technical tools for their IV workflow management system. Adding
MedKeeper to BD's Medication Management Solutions portfolio will
further strengthen the company's ability to deliver solutions that
best meet customers' needs – now and in the future.
"Demands in today's pharmacy environment, such as COVID-impacted
labor shortages and changing regulatory requirements, have further
exacerbated the need for customizable pharmacy software solutions
to support flexible, directed workflow, inventory tracking and
reporting needs in sterile and non-sterile compounding," said
Garrison. "Manual, time-consuming procedures that might once have
been 'good enough' now can be replaced and augmented by software
that enables pharmacists to provide a higher standard of care."
BD and MedKeeper will work to provide customers with flexibility
and capabilities in meeting industry standards for preparing
compounded medications, incorporating the latest regulatory
guidance. Together, the companies are dedicated to ensuring that
every customer has a workflow solution that best supports their
environment and delivers efficiencies to their frontline
clinicians.
The transaction is expected to be immaterial to BD's fiscal 2022
financial results.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the
world of health™ by improving medical discovery, diagnostics
and the delivery of care. The company supports the heroes on the
frontlines of health care by developing innovative technology,
services and solutions that help advance both clinical therapy for
patients and clinical process for health care providers. BD and its
70,000 employees have a passion and commitment to help enhance the
safety and efficiency of clinicians' care delivery process, enable
laboratory scientists to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. By working in
close collaboration with customers, BD can help enhance outcomes,
lower costs, increase efficiencies, improve safety and expand
access to health care. For more information on BD, please
visit bd.com or connect with us on LinkedIn
at www.linkedin.com/company/bd1/ and
Twitter @BDandCo.
FORWARD LOOKING STATEMENTS
This press release contains
certain estimates and other forward-looking statements (as defined
under Federal securities laws) regarding the anticipated benefits
of the acquisition of MedKeeper. Forward looking statements
generally are accompanied by words such as "will", "expect", or
similar words, phrases or expressions. These statements are based
on the current expectations of BD management and are subject to a
number of risks and uncertainties regarding MedKeeper's business
and the acquisition, and actual results may differ materially from
any anticipated results described, implied or projected in any
forward-looking statement. These risks and uncertainties include,
but are not limited to, risks relating to the integration of
MedKeeper's technology, software and employees into BD and the time
and resources required to do so and the possibility that the
anticipated benefits of the acquisition will not be realized or
will not be realized within the expected timeframe; competitive
factors, including the development of new technologies by other
companies and pricing and market share pressures; changes in
healthcare or other governmental regulation; risks relating to the
ability to maintain favorable supplier arrangements and
relationships; changes in regional, national or foreign economic
conditions, as well as other factors discussed in BD's filings with
the Securities Exchange Commission. BD does not intend to update
any forward-looking statements to reflect events or circumstances
after the date hereof, except as required by applicable laws or
regulations.
Contacts:
|
|
|
|
Media:
|
Investors:
|
Trey Hollern
|
Francesca
DeMartino
|
Director, Public
Relations
|
SVP, Head of Investor
Relations
|
862.284.8629
|
201.847.5743
|
trey.hollern@bd.com
|
francesca.demartino@bd.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bd-acquires-medkeeper-to-offer-cloud-based-connected-pharmacy-software-301594770.html
SOURCE BD (Becton, Dickinson and Company)